Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Psilocybin for treatment-resistant depression
ISRCTN14426797Phase 2Completed
- Sponsor
- Imperial College London
- Start
- Apr 2015
- Modality
- Small Molecules
01
Overview
Phase 2, open-label, single-arm trial of psilocybin in major depressive disorder (MDD), sponsored by Imperial College London. Primary endpoint: Quick Inventory of Depressive Symptoms. Started Apr 2015; status: completed.
02
Drugs
psilocybin
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on ISRCTN14426797.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN14426797.